I'm the Pluvicto repeat patient you are looking for. I was a clinical trial patient at the University of Chicago Medical Center for PSMA 617 LU177 in 2021-22 for Novartis Pharmaceutical. The USFDA approved the program in about late 2022 or 23 under the name Pluvicto. About 25 months later in 2024 and after exhausting other treatment options, arrangements were made with Novartis, Medicare, my supplemental insurance and my oncologist to repeat the 6 treatments. I've received 4 of the repeat 6. And, I am extremely happy to say, my response is, once again, remarkable. So much so, treatments 5 and 6 are temporarily paused to help reduce unwanted side effects and the remaining treatments can be administered at a later date.
This is a very rare situation, as insurance will only pay once. Since the first round of 6 treatments was a trial paid by the pharmaceutical company, the insurance providers viewed this 2nd round at their first. It is completely at my own risk. I'm kicking the perverbial cancer can down the road a little further, hopefully another couple of years.
Perhaps, by the time you need a second round (or I a 3rd), approval my be in place for this life saving treatment.
Stay in touch. I'm as curious about you as you are about me.